<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696722</url>
  </required_header>
  <id_info>
    <org_study_id>DM2ATV</org_study_id>
    <secondary_id>2006.00.055</secondary_id>
    <nct_id>NCT00696722</nct_id>
  </id_info>
  <brief_title>Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction</brief_title>
  <acronym>DM2ATV</acronym>
  <official_title>Influence of Atazanavir Treatment on Endothelial Dysfunction, Vascular Inflammation and Heme Oxygenase Activity in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether atazanavir use is of influence on the
      endothelial dysfunction associated with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acetylcholine induced vasodilation</measure>
    <time_frame>following a 4 day treatment with either placebo or atazanavir</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>heme oxygenase expression and activity</measure>
    <time_frame>following a 4 day treatment with either placebo or atazanavir</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of vascular inflammation by determination of adhesion molecule levels</measure>
    <time_frame>following a 4 day treatment with either placebo or atazanavir</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Type 2 Diabetes Mellitus Related Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo treatment first, atazanavir treatment second</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atazanavir treatment first, placebo treatment second</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo + atazanavir</intervention_name>
    <description>Placebo treatment first, atazanavir treatment second
4 day treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir + placebo</intervention_name>
    <description>Atazanavir treatment first, placebo treatment second
4 day treatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (most important):

          -  18 - 70 years

          -  type 2 diabetes mellitus treated with diet, oral medication and/or insulin

          -  BMI of 18 to 35

          -  determinants of renal and hepatic function within twice the upper limit of normal
             range, abnormalities in lipid profile permitted

        Exclusion Criteria (most important):

          -  history of smoking within past year

          -  history of or current abuse of drugs, alcohol or solvents

          -  current use of antihypertensive, cardiac or other vasoactive medication

          -  clinical evidence of cardiac or pulmonary disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <last_update_submitted>January 24, 2010</last_update_submitted>
  <last_update_submitted_qc>January 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>P. Smits</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

